Basilea Pharmaceutica Ltd. Logo
 
Search
 

News

 
 
Language
Year
Keyword
 
Tuesday, February 19. 2019
 
  • Total revenue increased 31% to CHF 133 million
  • Revenue from Cresemba® and Zevtera® increased 56% to CHF 82 million
  • Positive derazantinib phase 2 interim results and collaboration with Roche on combination with Tecentriq®
  • Year-end cash position of CHF 223 million
 
more...
 
Friday, February 08. 2019
 
Basel, Switzerland, February 08, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the European sales of the antifungal Cresemba® (isavuconazole) by Pfizer exceeded the threshold triggering the first sales milestone payment to Basilea of USD 5 million.
 
more...
 
Thursday, February 07. 2019
 

Basel, February 7, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Board of Directors has appointed Adesh Kaul, currently Chief Corporate Development Officer and member of the Management Committee, as the new Chief Financial Officer (CFO) as of April 10, 2019. He will succeed Donato Spota, who has decided to pursue a new opportunity outside the company. Mr. Spota will continue in his role until the Annual General Meeting on April 10, 2019.

 
more...
 
Thursday, January 24. 2019
 
Basel, Switzerland, January 24, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of Basilea's derazantinib and Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study mid-2019.
 
more...
 
Wednesday, January 09. 2019
 
  • 21% objective response rate with six confirmed partial responses from 29 evaluable patients
  • 83% disease control rate
  • Safety profile and tolerability of continuous dosing schedule confirmed
 
more...
 
Monday, January 07. 2019
 
Basel, Switzerland, January 07, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the unaudited preliminary revenue for the financial year 2018. Total revenue is expected to increase by 31% over 2017 to approx. CHF 133 million (FYR 2017: CHF 101.5 million), with contributions of approx. CHF 82 million (FYR 2017: CHF 52.5 million, + 56%) from Basilea's two marketed products, the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole). Basilea had guided for total revenue of CHF 120-130 million and contributions from Cresemba and Zevtera of CHF 75-85 million for the financial year 2018.
 
more...
 
Friday, January 04. 2019
 
Basel, Switzerland, January 04, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that David Veitch, Chief Executive Officer of Basilea, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019 at 8:30 a.m. Pacific Standard Time / 5:30 p.m. Central European Time at the Westin St. Francis Hotel, San Francisco, CA.
 
more...
 
Monday, December 10. 2018
 
Basel, Switzerland, December 10, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) by Astellas Pharma Inc. ("Astellas") in the United States exceeded the threshold triggering a milestone payment to Basilea in the amount of CHF 10 million.
 
more...
 
Wednesday, November 14. 2018
 
  • Late-breaking abstracts on increased cure rates and synergistic effects of combinations with eribulin and gemcitabine in solid tumor models
  • Enhanced survival in a brain tumor model after single agent treatment
 
more...
 
Tuesday, August 14. 2018
 
  • Total revenue increased by 30% to CHF 59.9 million; 2018 total revenue guidance is increased to CHF 120 - 130 million
  • Royalties on Cresemba sales more than doubled to CHF 10.8 million
  • Clinical oncology pipeline strengthened through in-licensing of phase 2 panFGFR kinase inhibitor (derazantinib)
  • Significant progress made in clinical programs
  • Cash position of CHF 247.3 million
 
more...
 
more
Info